RxDoctor Payments Data

Sheetal Sharma, MD

Gastroenterology · Washington, MONPI 1538328885

Payments from drug & device makers

$1,122in general payments, 2019–2025

Across 37 payments — averaging $30.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$475
  • Pfizer$226
  • AbbVie$170
  • Takeda Pharmaceuticals U.S.A., Inc.$73
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$35
  • Shionogi Inc$31
  • plus $112 from 6 others

What the payments were for

  • Food & beverage$1,122100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,122 in reported general payments places this provider in the 40th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$63,715
Medicare patients
244
Services billed
483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$346,043
CreonLipase/Protease/Amylase15$55,137
XifaxanRifaximin13$37,335
LinzessLinaclotide37$27,156
Mesalamine18$14,273
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates51$3,333
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl182$3,101
Ursodiol17$2,775
Omeprazole122$1,859
Mesalamine ErMesalamine30$1,789
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl87$1,186
Dicyclomine Hcl56$828
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl60$771
CholestyramineCholestyramine (With Sugar)12$756
Ondansetron Hcl334$644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$29$346,04312 claims
AbbVieCreon, Linzess$170$82,29352 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$35$37,33513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in Washington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →